GeneOne Life Science, Inc. (KRX:011000)
787.00
+67.00 (9.31%)
Last updated: Apr 16, 2026, 2:23 PM KST
GeneOne Life Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -51,851 | -48,537 | -77,768 | -38,150 | -15,888 |
Depreciation & Amortization | 18,196 | 17,961 | 12,776 | 5,424 | 4,650 |
Loss (Gain) From Sale of Assets | -43.83 | -2.82 | -3.4 | -1.31 | 106.64 |
Asset Writedown & Restructuring Costs | - | - | 32,309 | - | - |
Loss (Gain) From Sale of Investments | - | 4.25 | - | - | - |
Provision & Write-off of Bad Debts | 157 | 2.7 | -845.52 | 1,293 | 111.17 |
Other Operating Activities | 11,010 | 8,442 | 3,171 | 3,579 | -2,084 |
Change in Accounts Receivable | 5,069 | 407.86 | 4,835 | -2,848 | 68.06 |
Change in Inventory | 2,005 | -2,096 | -207.63 | -4,256 | -2,415 |
Change in Accounts Payable | 3,456 | 10,240 | 3,801 | -10,003 | 10,610 |
Change in Income Taxes | - | - | - | - | -97.74 |
Change in Other Net Operating Assets | -4,416 | -1,987 | 188.33 | 20,850 | -194.83 |
Operating Cash Flow | -16,541 | -16,058 | -21,744 | -24,113 | -4,849 |
Capital Expenditures | -23.82 | -3,298 | -5,601 | -45,306 | -82,442 |
Sale of Property, Plant & Equipment | 48.18 | 2.12 | 15.7 | - | 29.13 |
Sale (Purchase) of Intangibles | -35.25 | -69.14 | -51.59 | -101.81 | -75.24 |
Investment in Securities | -698 | 470.79 | 31,529 | 53,000 | -57,000 |
Other Investing Activities | 434 | 46 | -0 | -151.33 | -5,961 |
Investing Cash Flow | -769.89 | -2,845 | 25,892 | 8,055 | -146,398 |
Short-Term Debt Issued | 30,873 | 1,352 | 3,792 | 701.15 | 1,054 |
Long-Term Debt Issued | 6,246 | 9,224 | 6,271 | 11,469 | - |
Total Debt Issued | 37,119 | 10,576 | 10,063 | 12,171 | 1,054 |
Short-Term Debt Repaid | -16,879 | -506.85 | -2,100 | - | -150.86 |
Long-Term Debt Repaid | -3,836 | -2,700 | -18,712 | -5,537 | -1,639 |
Total Debt Repaid | -20,715 | -3,207 | -20,812 | -5,537 | -1,790 |
Net Debt Issued (Repaid) | 16,404 | 7,369 | -10,749 | 6,633 | -735.35 |
Issuance of Common Stock | 1,000 | 3,590 | 2,470 | 382.44 | 112,609 |
Other Financing Activities | 46.91 | -0 | -5.64 | -2.97 | -849.86 |
Financing Cash Flow | 17,451 | 10,959 | -8,285 | 7,013 | 111,023 |
Foreign Exchange Rate Adjustments | -1.18 | 13.81 | -13.29 | -3.42 | 101.37 |
Miscellaneous Cash Flow Adjustments | -0 | 0 | - | 0 | 0 |
Net Cash Flow | 138.54 | -7,931 | -4,150 | -9,049 | -40,122 |
Free Cash Flow | -16,565 | -19,356 | -27,345 | -69,419 | -87,291 |
Free Cash Flow Margin | -71.88% | -54.19% | -68.02% | -142.49% | -225.56% |
Free Cash Flow Per Share | -200.95 | -243.66 | -351.70 | -895.90 | -1175.77 |
Cash Interest Paid | 54.26 | 74.66 | 82.15 | 58.5 | - |
Cash Income Tax Paid | -103.42 | -236.05 | 104.9 | 326.55 | 189.71 |
Levered Free Cash Flow | 3,487 | 2,211 | -22,581 | -73,691 | -103,116 |
Unlevered Free Cash Flow | 6,700 | 3,558 | -21,843 | -69,123 | -100,332 |
Change in Working Capital | 5,991 | 6,071 | 8,617 | 3,743 | 8,255 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.